AstraZeneca's Forxiga (dapagliflozin) Receives EU's Approval for Type-1 Diabetes (T1D) in Adults
Shots:
- The approval is based on P-III two DEPICT study results DEPICT 1 (NCT02268214) & DEPICT 2 (NCT02460978) assessing Forxiga (5/10 mg) vs PBO in patients with T1D inadequately controlled by insulin for 24 to 52 wks.
- The study resulted in meeting its 1EPs & 2EPs as reductions in average blood glucose levels HbA1c weight and total daily insulin dose for 24 & 52 wks. demonstrating safe and effective results
- Forxiga (dapagliflozinm- qd- PO) is a novel inhibitor of human sodium-glucose co-transporter 2 (SGLT2) and is currently under review in Japan & the US as an adjunct treatment to insulin in adults with T1D with expected approval in Q1’19 and Q2’19 respectively
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com